• First Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus Receives US FDA EUA

Laboratory Products

First Syndromic Solution Integrating Detection of SARS-CoV-2 Coronavirus Receives US FDA EUA

Apr 02 2020

Qiagen has announced that it has received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for use in diagnosing patients infected with the novel COVID-19 coronavirus.

The QIAstat-Dx test kit can differentiate the SARS-CoV-2 coronavirus from 21 other serious respiratory infections in patients who may have similar symptoms in a single testing run of about one hour. It is a multiplexed nucleic acid test that evaluates samples such as nasopharyngeal swabs obtained from individuals suspected of respiratory tract infections. The newly approved panel includes assays targeting two genes used to detect the pathogen behind the disease, Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2), and is intended for use in laboratories certified under CLIA to perform moderate and high complexity tests.

“We are pleased to begin making QIAstat-Dx SARS-CoV-2 test kits available in the United States under the FDA’s emergency use authorisation for clinical laboratories. The QIAstat-Dx syndromic panel adds an important tool for clinicians,” said Thierry Bernard, Chief Executive Officer at Qiagen. “I am proud of our Qiagen teams working tirelessly to implement 24/7 production of test cartridges and testing components. In addition to QIAstat-Dx, we are supplying RNA extraction kits under the QIAamp and EZ1 brands as well as numerous components and instruments for use in fighting this public health crisis around the world.”

The EUA approval status comes after Qiagen announced on 24 March that it had begun shipping QIAstat-Dx SARS-CoV-2 test kits to the United States under a new FDA Policy allowing the kits to be made commercially available.

The automation system enables fast, cost-effective and easy-to-use syndromic testing with Sample to Insight workflows. A technician simply loads a clinical sample (such as a swab) into a single-use QIAstat-Dx cartridge and places it in the analyser. Qiagen chemistries for DNA and RNA sample processing and analysis are built into the instrument, and the QIAstat-Dx instrument delivers results in about one hour.

More information online


Digital Edition

Lab Asia 31.1 - February 2024

February 2024

In This Edition Chromatography Articles - Comparing techniques for flow rate measurement in Liquid Chromatography Mass Spectrometry & Spectroscopy Articles - APGC: A Better Future with...

View all digital editions

Events

PITTCON 2024

Feb 24 2024 San Diego, CA, USA

Asia Pharma Expo/Asia Lab Expo

Feb 29 2024 Dhaka, Bangladesh

Nepal Lab

Feb 29 2024 Kathmandu, Nepal

IFPAC 2024

Mar 03 2024 Bethesda, MA, USA

SIAF Guangzhou

Mar 04 2024 Guanghzou, China

View all events